{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T05:48:13Z","timestamp":1697262493107},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr hepatitis rep"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s11901-008-0022-2","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T06:52:43Z","timestamp":1224053563000},"page":"97-105","source":"Crossref","is-referenced-by-count":11,"title":["Hepatitis C viral kinetics in special populations"],"prefix":"10.1007","volume":"7","author":[{"given":"Harel","family":"Dahari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer E.","family":"Layden-Almer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan S.","family":"Perelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Layden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,16]]},"reference":[{"key":"22_CR1","first-page":"S3","volume":"36","author":"National Institutes of Health","year":"2002","unstructured":"National Institutes of Health: National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002, 36:S3\u2013S20.","journal-title":"Hepatology"},{"key":"22_CR2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2893.1996.tb00084.x","volume":"3","author":"T.T. Nguyen","year":"1996","unstructured":"Nguyen TT, Sedghi-Vaziri A, Wilkes LB, et al.: Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 1996, 3:75\u201378.","journal-title":"J Viral Hepat"},{"key":"22_CR3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","volume":"282","author":"A.U. Neumann","year":"1998","unstructured":"Neumann AU, Lam NP, Dahari H, et al.: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103\u2013107.","journal-title":"Science"},{"key":"22_CR4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1086\/315661","volume":"182","author":"A.U. Neumann","year":"2000","unstructured":"Neumann AU, Lam NP, Dahari H, et al.: Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000, 182:28\u201335.","journal-title":"J Infect Dis"},{"key":"22_CR5","first-page":"345A","volume":"34","author":"C.C. Bergmann","year":"2001","unstructured":"Bergmann CC, Layden JE, Levy-Drummer RS, et al.: Clinical implications of a new tri-phasic model for hepatitis C viral kinetics during IFN-alpha therapy [abstract]. Hepatology 2001, 34:345A.","journal-title":"Hepatology"},{"key":"22_CR6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/jhep.2003.50218","volume":"37","author":"E. Herrmann","year":"2003","unstructured":"Herrmann E, Lee JH, Marinos G, et al.: Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003, 37:1351\u20131358.","journal-title":"Hepatology"},{"key":"22_CR7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/hep.21781","volume":"46","author":"T.L. Kieffer","year":"2007","unstructured":"Kieffer TL, Sarrazin C, Miller JS, et al.: Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007, 46:631\u2013639.","journal-title":"Hepatology"},{"key":"22_CR8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/jhep.2002.31773","volume":"35","author":"M. Garcia-Retortillo","year":"2002","unstructured":"Garcia-Retortillo M, Forns X, Feliu A, et al.: Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002, 35:680\u2013687.","journal-title":"Hepatology"},{"key":"22_CR9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jhep.2004.12.017","volume":"42","author":"H. Dahari","year":"2005","unstructured":"Dahari H, Feliu A, Garcia-Retortillo M, et al.: Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol 2005, 42:491\u2013498.","journal-title":"J Hepatol"},{"key":"22_CR10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/lt.20572","volume":"12","author":"K.A. Powers","year":"2006","unstructured":"Powers KA, Ribeiro RM, Patel K, et al.: KInetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006, 12:207\u2013216.","journal-title":"Liver Transpl"},{"key":"22_CR11","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.20947","volume":"42","author":"T.D. Schiano","year":"2005","unstructured":"Schiano TD, Gutierrez JA, Walewski JL, et al.: Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology 2005, 42:1420\u20131428.","journal-title":"Hepatology"},{"key":"22_CR12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/373123a0","volume":"373","author":"D.D. Ho","year":"1995","unstructured":"Ho DD, Neumann AU, Perelson AS, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123\u2013126.","journal-title":"Nature"},{"key":"22_CR13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/373117a0","volume":"373","author":"X. Wei","year":"1995","unstructured":"Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117\u2013122.","journal-title":"Nature"},{"key":"22_CR14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1053\/j.gastro.2005.01.049","volume":"128","author":"H. Dahari","year":"2005","unstructured":"Dahari H, Major M, Zhang X, et al.: Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology 2005, 128:1056\u20131066.","journal-title":"Gastroenterology"},{"issue":"Suppl1","key":"22_CR15","first-page":"13","volume":"23","author":"K.A. Powers","year":"2003","unstructured":"Powers KA, Dixit NM, Ribeiro RM, et al.: Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis 2003, 23(Suppl 1):13\u201318.","journal-title":"Semin Liver Dis"},{"key":"22_CR16","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.21136","volume":"43","author":"A.H. Talal","year":"2006","unstructured":"Talal AH, Ribeiro RM, Powers KA, et al.: Pharmacodynamics of PEG-IFN alpha differentiate HIV\/HCV coinfected sustained virological responders from nonresponders. Hepatology 2006, 43:943\u2013953.","journal-title":"Hepatology"},{"key":"22_CR17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1053\/jhep.2003.50344","volume":"38","author":"R.M. Ribeiro","year":"2003","unstructured":"Ribeiro RM, Layden-Almer J, Powers KA, et al.: Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 2003, 38:509\u2013517.","journal-title":"Hepatology"},{"key":"22_CR18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/135965350300800602","volume":"8","author":"P. Colombatto","year":"2003","unstructured":"Colombatto P, Civitano L, Oliveri F, et al.: Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir Ther 2003, 8:519\u2013530.","journal-title":"Antivir Ther"},{"key":"22_CR19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/hep.510260130","volume":"26","author":"N.P. Lam","year":"1997","unstructured":"Lam NP, Neumann AU, Gretch DR, et al.: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997, 26:226\u2013231.","journal-title":"Hepatology"},{"key":"22_CR20","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1126\/science.290.5498.1972","volume":"290","author":"K.J. Blight","year":"2000","unstructured":"Blight KJ, Kolykhalov AA, Rice CM: Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290:1972\u20131974.","journal-title":"Science"},{"key":"22_CR21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","volume":"432","author":"N.M. Dixit","year":"2004","unstructured":"Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS: Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004, 432:922\u2013924.","journal-title":"Nature"},{"key":"22_CR22","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1053\/jhep.2003.50217","volume":"37","author":"J.E. Layden-Almer","year":"2003","unstructured":"Layden-Almer JE, Ribeiro RM, Wiley T, et al.: Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003, 37:1343\u20131350.","journal-title":"Hepatology"},{"key":"22_CR23","first-page":"361A","volume":"46","author":"G. Bortoletto","year":"2007","unstructured":"Bortoletto G, Realdon S, Dal Pero F, et al.: Insulin resistance (IR) defined by the homeostasis model of assessment insulin resistance (HOMA-IR) index has a direct effect on early viral kinetics during pegylated-interferon therapy for chronic hepatitis C [abstract]. Hepatology 2007, 46:361A.","journal-title":"Hepatology"},{"key":"22_CR24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1023\/A:1018865928308","volume":"42","author":"N.P. Lam","year":"1997","unstructured":"Lam NP, Pitrak D, Speralakis R, et al.: Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci 1997, 42:178\u2013185.","journal-title":"Dig Dis Sci"},{"key":"22_CR25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2893.2006.00777.x","volume":"14","author":"J. Westin","year":"2007","unstructured":"Westin J, Lagging M, Dhillon AP, et al.: Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat 2007, 14:29\u201335.","journal-title":"J Viral Hepat"},{"key":"22_CR26","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.3748\/wjg.v12.i45.7271","volume":"12","author":"J.E. Medeiros-Filho","year":"2006","unstructured":"Medeiros-Filho JE, de Carvalho Mello IM, Pinho JR, et al.: Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy. World J Gastroenterol 2006, 12:7271\u20137277.","journal-title":"World J Gastroenterol"},{"key":"22_CR27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1365-2893.2003.00401.x","volume":"10","author":"S.J. Cotler","year":"2003","unstructured":"Cotler SJ, Layden JE, Neumann AU, Jensen DM: First phase hepatitis c viral kinetics in previous nonresponders patients. J Viral Hepat 2003, 10:43\u201349.","journal-title":"J Viral Hepat"},{"issue":"Suppl1","key":"22_CR28","first-page":"473A","volume":"40","author":"A.U. Neumann","year":"2004","unstructured":"Neumann AU, Mohan P, Lutchman G, et al.: Hepatitis C viral kinetics in children treated with PEGIFN alfa-2a [abstract]. Hepatology 2004, 40(Suppl 1):473A.","journal-title":"Hepatology"},{"key":"22_CR29","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1086\/379255","volume":"188","author":"F.J. Torriani","year":"2003","unstructured":"Torriani FJ, Ribeiro RM, Gilbert TL, et al.: Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV\/HIV coinfection. J Infect Dis 2003, 188:1498\u20131507.","journal-title":"J Infect Dis"},{"key":"22_CR30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1046\/j.1365-2893.2002.00377.x","volume":"9","author":"J.E. Layden","year":"2002","unstructured":"Layden JE, Layden TJ, Reddy KR, et al.: First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 2002, 9:340\u2013345.","journal-title":"J Viral Hepat"},{"key":"22_CR31","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(01)06356-5","volume":"358","author":"W. Jessner","year":"2001","unstructured":"Jessner W, Gschwantler M, Steindl-Munda P, et al.: Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001, 358:1241\u20131242.","journal-title":"Lancet"},{"key":"22_CR32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jhep.2007.01.027","volume":"47","author":"H. Dahari","year":"2007","unstructured":"Dahari H, Markatou M, Zeremski M, et al.: Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV\/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007, 47:23\u201330.","journal-title":"J Hepatol"},{"key":"22_CR33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2004.11.059","volume":"128","author":"K.E. Sherman","year":"2005","unstructured":"Sherman KE, Shire NJ, Rouster SD, et al.: Viral kinetics in hepatitis C or hepatitis C\/human immunodeficiency virus-infected patients. Gastroenterology 2005, 128:313\u2013327.","journal-title":"Gastroenterology"},{"key":"22_CR34","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","volume":"132","author":"C. Sarrazin","year":"2007","unstructured":"Sarrazin C, Kieffer TL, Bartels D, et al.: Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767\u20131777.","journal-title":"Gastroenterology"},{"key":"22_CR35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1053\/j.gastro.2003.12.002","volume":"126","author":"J.M. Pawlotsky","year":"2004","unstructured":"Pawlotsky JM, Dahari H, Neumann AU, et al.: Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004, 126:703\u2013714.","journal-title":"Gastroenterology"},{"key":"22_CR36","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1053\/gast.2001.24006","volume":"120","author":"S. Zeuzem","year":"2001","unstructured":"Zeuzem S, Herrmann E, Lee JH, et al.: Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001, 120:1438\u20131447.","journal-title":"Gastroenterology"},{"key":"22_CR37","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1053\/j.gastro.2007.06.059","volume":"133","author":"M. Pilli","year":"2007","unstructured":"Pilli M, Zerbini A, Penna A, et al.: HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 2007, 133:1132\u20131143.","journal-title":"Gastroenterology"},{"key":"22_CR38","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/hep.21587","volume":"45","author":"K. Inoue","year":"2007","unstructured":"Inoue K, Umehara T, Ruegg UT, et al.: Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 2007, 45:921\u2013928.","journal-title":"Hepatology"},{"key":"22_CR39","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/hep.21798","volume":"46","author":"H. Dahari","year":"2007","unstructured":"Dahari H, Perelson AS: Hepatitis C virus kinetics in chimeric mice during antiviral therapy. Hepatology 2007, 46:2048\u20132049.","journal-title":"Hepatology"},{"key":"22_CR40","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1128\/JCM.00577-07","volume":"45","author":"M. Lindh","year":"2007","unstructured":"Lindh M, Alestig E, Arnholm B, et al.: Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. J Clin Microbiol 2007, 45:2439\u20132445.","journal-title":"J Clin Microbiol"},{"key":"22_CR41","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.3748\/wjg.v13.i21.3020","volume":"13","author":"H. Dahari","year":"2007","unstructured":"Dahari H, Perelson AS: Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss. World J Gastroenterol 2007, 13:3020\u20133021.","journal-title":"World J Gastroenterol"},{"key":"22_CR42","first-page":"390A","volume":"40","author":"R.S. Levy-Drummer","year":"2004","unstructured":"Levy-Drummer RS, Haagmans BL, Soulier A, et al.: Pharmacodynamic modeling of HCV kinetics during peg-interferon-alfa-2a (40KD) and ribavirin treatment of chronic hepatitis C genotype 1 patients in the DITTO-HCV study [abstract]. Hepatology 2004, 40:390A.","journal-title":"Hepatology"},{"key":"22_CR43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-230X-1-14","volume":"1","author":"F.C. Bekkering","year":"2001","unstructured":"Bekkering FC, Neumann AU, Brouwer JT, et al.: Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study. BMC Gastroenterol 2001, 1:14.","journal-title":"BMC Gastroenterol"},{"key":"22_CR44","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jtbi.2007.03.006","volume":"247","author":"H. Dahari","year":"2007","unstructured":"Dahari H, Lo A, Ribeiro RM, Perelson AS: Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol 2007, 247:371\u2013381.","journal-title":"J Theor Biol"},{"key":"22_CR45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1006\/jtbi.1997.0622","volume":"192","author":"L.M. Wein","year":"1998","unstructured":"Wein LM, D\u2019Amato RM, Perelson AS: Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J Theor Biol 1998, 192:81\u201398.","journal-title":"J Theor Biol"},{"key":"22_CR46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/bulm.2001.0266","volume":"64","author":"D.S. Callaway","year":"2002","unstructured":"Callaway DS, Perelson AS: HIV-1 infection and low steady state viral loads. Bull Math Biol 2002, 64:29\u201364.","journal-title":"Bull Math Biol"},{"key":"22_CR47","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1128\/JVI.80.5.2280-2290.2006","volume":"80","author":"S. Pal","year":"2006","unstructured":"Pal S, Shuhart MC, Thomassen L, et al.: Intrahepatic hepatitis C virus replication correlates with chronic hepatitis C disease severity in vivo. J Virol 2006, 80:2280\u20132290.","journal-title":"J Virol"},{"key":"22_CR48","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.21440","volume":"44","author":"G.T. Everson","year":"2006","unstructured":"Everson GT, Hoefs JC, Seeff LB, et al.: Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006, 44:1675\u20131684.","journal-title":"Hepatology"},{"key":"22_CR49","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jhep.2006.08.020","volume":"46","author":"A. Iacobellis","year":"2007","unstructured":"Iacobellis A, Siciliano M, Perri F, et al.: Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007, 46:206\u2013212.","journal-title":"J Hepatol"},{"key":"22_CR50","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/hep.21657","volume":"46","author":"H. Dahari","year":"2007","unstructured":"Dahari H, Ribeiro RM, Perelson AS: Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 2007, 46:16\u201321.","journal-title":"Hepatology"}],"container-title":["Current Hepatitis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11901-008-0022-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11901-008-0022-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11901-008-0022-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T12:15:29Z","timestamp":1684584929000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11901-008-0022-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["22"],"URL":"https:\/\/doi.org\/10.1007\/s11901-008-0022-2","relation":{},"ISSN":["1540-3416","1541-0706"],"issn-type":[{"value":"1540-3416","type":"print"},{"value":"1541-0706","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}